Industry Experts

Alain Tissot is Vice President, Lead Therapeutic Antibodies at Bayer. He brings more than 16 years of experience in bispecific antibodies, covering multiple modes of action, including targeted and non-targeted agonists, brain delivery, antagonists, T cell engagers, and targeted cytokines. Before joining Bayer, he was responsible for portfolios of biologics and bispecific antibodies in the fields of immunology, neuroscience, ophthalmology and onco-immunology. This included an additional focus on DMPK and immunogenicity questions. He has also led a department focused on in vivo antibody generation with high-throughput B cell cloning, antibody cloning, expression and purification